dwinnex.com

Idera Pharmaceuticals, Inc. [NASDAQ:IDRA]: Analyst Rating and Earnings

Stock market traders frequently keep their eyes on what Wall Street experts as it relates to a potential investment. For Idera Pharmaceuticals, Inc. [IDRA], the most recent analyst consensus recommendation available since its latest financial results for the quarter ending in December. On average, stock market experts give IDRA an Outperform rating. Its stock price has been found in the range of 2.25 to 16.32. This is compared to its latest closing price of $2.64.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Idera Pharmaceuticals, Inc. [IDRA] is sitting at 1.67. This is compared to 1 month ago, when its average rating was 1.67.

Keep your eyes peeled for the soon-to-be-published financial results of this company, which are expected to be made public on Thu 1 Aug (In 51 Days).

Fundamental Analysis of Idera Pharmaceuticals, Inc. [IDRA]

Now let’s turn to look at profitability: with a current Operating Margin for Idera Pharmaceuticals, Inc. [IDRA] sitting at -8549.70.

This company’s Return on Total Capital is -65.85, and its Return on Invested Capital has reached -95.20%. Its Return on Equity is -69.76, and its Return on Assets is -62.56. These metrics suggest that this Idera Pharmaceuticals, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

What about valuation? This company’s Enterprise Value to EBITDA is -0.05. The Enterprise Value to Sales for this firm is now 6.26. Idera Pharmaceuticals, Inc. [IDRA] has a Price to Book Ratio of 1.18.

Shifting the focus to workforce efficiency, Idera Pharmaceuticals, Inc. [IDRA] earns $18,389 for each employee under its payroll. Similarly, this company’s Total Asset Turnover is 0.01. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 8.07 and its Current Ratio is 8.07. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Idera Pharmaceuticals, Inc. [IDRA] has 27.92M shares outstanding, amounting to a total market cap of $80.41M. Its stock price has been found in the range of 2.25 to 16.32. At its current price, it has moved by -82.35% from its 52-week high, and it has moved 28.00% from its 52-week low.

This stock’s Beta value is currently 2.50, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 54.79. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Idera Pharmaceuticals, Inc. [IDRA] a Reliable Buy?

Idera Pharmaceuticals, Inc. [IDRA] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.